Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Theralase Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (PDCs) and their associated drug formulations intended to safely and effectively destroy various cancers recently announced the Chinese Patent Office has Issued a Notice of Acceptance for a patent application concerning Multiwavelength PhotoDynamic Therapy (PDT) to the company.
The patent, titled, Apparatus and Method for Multiwavelength PhotoDynamic Therapy, validates the proprietary position of the company and opens opportunities for the application of Theralase’s PDT technology in an international market.
“Theralase continues to advance it’s Anti-Cancer Therapy (ACT) through optimization of the technology and protecting those advancements through a comprehensive intellectual property strategy. This new multiwavelength laser system is the latest addition to our technology platform, allowing the activation of PDCs at various wavelengths, sequentially or simultaneously, to destroy cancerous targets at correspondingly different tissue depths. Our long-term strategy is to commercialize the ACT technology to provide an alternative treatment option for patients inflicted with this deadly disease. The ability to provide personalized ACT treatment for cancer patients to destroy their cancer permanently and prevent its recurrence, all in a single treatment, remains at the forefront of our minds. China is the fourth largest medical device market in the world behind the US, Japan, and Germany, and represents a new opportunity for Theralase and our expanding platform of technologies,” said Kipton P. Lade, CEO – Device Division, Theralase.
Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. For more information, visit www.theralase.com and www.sedar.com.
Total Page Views: 137